Business
Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors
PALO ALTO, Calif., Dec. 19, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., Dec. 19, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Taiyin Yang, Ph.D., to its board of directors. Currently, Dr. Yang serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc.\n\"Dr. Yang joins our board in a growth phase for Kodiak as we pursue our 2022 Vision for KSI-301 in retinal vein occlusion, wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy and our anticipated Biologics License Application (BLA) and supplemental BLA submissions,\" said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. \"Dr. Yang's deep experience with product development, commercial manufacturing and quality operations will be instrumental as we advance KSI-301 and our deepening pipeline of bi-specific and triplet ABC product candidates.\"\nDr. Yang joined Gilead in 1993 and was appointed to her current role of Executive Vice President, Pharmaceutical Development and Manufacturing in January 2015. She is responsible for chemistry, manufacturing and control operations of small molecules and biologics encompassing process development, production, supply chain management, analytical operations, laboratory information and quality assurance for Gilead's investigational and commercial products. She received her bachelor's degree in Chemistry from National Taiwan University and her Ph.D. in Organic Chemistry from the University of Southern California.\n\"Kodiak has made important pipeline progress, and I am delighted to join the board of directors during this important expansion phase for the company,\" said Dr. Yang. \"I look forward to working with the Kodiak team and contributing to Kodiak's future growth and success as the company executes pivotal development activities with the potential to change patients' lives.\"\nAbout Kodiak Sciences Inc. \nKodiak™ is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Plat...